Pediatric Oncology Keeps Getting Treated as an Afterthought. The Biology Disagrees.

"The biology has been pointing in this direction for a decade. The regulatory architecture is in place. The incentives exist. What happens in the next generation of molecularly targeted oncology programs will depend on whether protocol teams treat that nine-year-old’s NTRK fusion as a scheduling problem for post-approval — or as the enrollment criterion she was always supposed to be."

Read more: https://www.clinicaltrialvanguard.com/opinion/pediatric-oncology-keeps-getting-treated-as-an-afterthought-the-biology-disagrees/